Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other neoplasm 1

Conditions

Breast Neoplasms 17Carcinoma, Non-Small-Cell Lung 14Lung Neoplasms 13Colorectal Neoplasms 11Rectal Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia 10Head and Neck Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Leukemia, Myeloid, Acute 8Colonic Neoplasms 8Kidney Neoplasms 7Congenital Abnormalities 7Carcinoma, Renal Cell 7Multiple Myeloma 6Lymphoma, Large B-Cell, Diffuse 6Gliosarcoma 6Glioblastoma 6Melanoma 5Lymphoma, Mantle-Cell 5Lymphoma, Large-Cell, Anaplastic 5Esophageal Neoplasms 5Central Nervous System Neoplasms 5Stomach Neoplasms 4Prostatic Neoplasms 4Precancerous Conditions 4Myelodysplastic Syndromes 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4

Interventions

Dexamethasone 14Lenalidomide 13Calcium Dobesilate 7carfilzomib 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Melphalan 3Leflunomide 3Curcumin 3isatuximab 2iberdomide 2daratumumab 2Denosumab 2Cyclophosphamide 2Bortezomib 2selinexor 1pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1elotuzumab 1citarinostat 1atezolizumab 1Urination 1Transplantation, Autologous 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Smoldering Multiple Myeloma × Gene Expression Profiling × Clear all
NCT00942422 2015-03-27

Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma

Barbara Ann Karmanos Cancer Institute

Phase 2 Terminated
8 enrolled 5 charts
Other neoplasmPlasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡